-
Kelun-Biotech to Present SKB264 Study Results for Metastatic Breast Cancer at ESMO
•
China-based pharmaceutical innovator Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) and its subsidiary Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) are preparing to present the results of a Phase I/II basket study for their drug SKB264 (MK-2870) at the 2023 European Society for Medical Oncology (ESMO) Congress. The study focuses…
-
China’s 9th National VBP Round Sets Rules for 42 Drugs Tender
•
The national drug alliance procurement office has issued a notification detailing the tendering rules for the 9th national Volume-Based Procurement (VBP) round, along with the finalized drug list. This round involves a total of 42 drugs, spanning 12 treatment areas and representing a market value of RMB 10.963 billion (USD…
-
Vcanbio Receives NMPA Approval for Stem Cell Therapy VUM02 Clinical Trial
•
China-based biotechnology firm Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a multi-center, randomized, double-blind, placebo-controlled Phase I/II study. The study will assess the efficacy and safety of its innovative product VUM02, a…
-
Nona Biosciences Partners with Ingenia for Immunological Therapeutics Development
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142) and a biotech company with operations in the Netherlands, the United States, and China, has formed a strategic partnership with Ingenia Therapeutics, a pre-clinical biotech with a presence in the United States and South Korea. The collaboration aims to…
-
SciClone Pharmaceuticals Gains FDA Nod for Thymalfasin COVID-19 Vaccine Booster Study
•
SciClone Pharmaceuticals Inc. (HKG: 6600), formerly a US-based and Nasdaq-listed company, has announced that it has received approval from the US FDA to conduct a clinical study for its drug thymalfasin as a booster for COVID-19 mRNA vaccines. This marks a significant step in exploring new ways to enhance the…
-
Atom Bioscience Secures $82M Series D to Advance Gout Treatment ABP-671
•
China-based Atom Bioscience, known formally as Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd, has reportedly raised over RMB 600 million (USD 82 million) in a Series D financing round. This follows a GTJA Investment-led Series C financing round in January 2022, which raised RMB 300 million (USD 41 million). The…
-
Shanghai Pharma Health Commerce Secures $68M in Series C Funding Round
•
Shanghai Pharma Health Commerce Co., Ltd, a distinguished former subsidiary of China’s pharmaceutical giant Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607), has reportedly secured RMB 500 million (USD 68 million) in a Series C financing round. This substantial investment underscores the company’s robust growth and potential within the healthcare sector.…
-
Hainan Poly Pharm’s PL002 Accepted for FDA Review for Liver Cancer Surgery
•
China-based pharmaceutical company Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that the Investigational New Drug (IND) filing for its novel injectable PL002 has been accepted for review by the US Food and Drug Administration (FDA). The drug is indicated for preoperative diagnosis and intraoperative navigation in patients with…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis Novo Nordisk NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
